NA-931, a novel quadruple IGF-1, GLP-1 and GIP Incretin Receptor Agonist Reduces Body Weight without Muscle Loss

Lloyd L. Tran

Biomed Industries Inc, USA

Biography :

Lloyd L. Tran is the Chief Executive Officer and of Biomed Industries, Inc. since May 2020. Previously, he served as Chief Scientific Officer at NeuroActiva, Inc, Director of Research & Development at Biomed Pharmaceutical, Inc. Lloyd began his career as a scientist at G.D. Searle, Monsanto (Bayer), and Pfizer. Dr. Tran earned a B.Sc (Honours) in Chemistry from the University of Otago and completed a Ph.D. in Medicinal Chemistry from the University of Wellington, New Zealand.

Abstract :

Biomed will present results of the Phase 1 clinical trial of an oral tablet formulation of NA- 931, a quadruple agonist of the insulin-like growth hormone- (IGF-1), glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors, in development for the potential treatment of metabolic disorders such as obesity.

Body Weight Reductions: In the 28-day study, subjects receiving NA-931 (n=42) demonstrat­ed dose-dependent reductions in mean body weight from baseline, ranging up to 6.4%. For doses ≥60 mg, placebo-adjusted reductions in mean body weight were maintained or im­proved at Day 35, seven days after the last dose of NA-931 was administered, ranging up to 4.8% relative to placebo. An exploratory assessment of the proportion of subjects achieving at least 5% weight loss after 28 days demonstrated that up to 63% of NA-931-treated subjects achieved ≥5% weight loss, compared with 0% for placebo.

Safety and Tolerability: NA-931 demonstrated encouraging safety and tolerability following 28 days of once-daily dosing. Among subjects receiving NA-931, emergent adverse events (TEAEs) were reported to date have been insignificant or mild All observed gastrointesti­nal (GI) adverse events have been reported as insignificant or mild, with the majority (84%) reported as insignificant. Mild nausea and vomiting were not reported among any NA-931- treated subjects. Diarrhea was reported in one subject (2.3%) receiving NA-931 compared with two subjects (10%) receiving placebo. Overall, no clinically meaningful differences were reported for GI-related adverse events among subjects treated with NA-931 compared with placebo. In addition, no serious adverse events (SAEs) have been reported to date.

Conclusion: Based on a preliminary evaluation of weight loss trajectory, Biomed believes the treatment beyond 28 days and may provide further reductions in body weight. The company has initiated a Phase 2 trial with the oral formulation of NA-931 in obesity in summer 2024.